• CRCL/CLB Seminar

Two CRCL/CLB seminars will take place this week :

  • Thursday 23rd of January at 10.00 am in the ONCORA meeting room (CLB, 2nd floor).
    We are pleased to welcome Ievgenia PASTUSHENKO (Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles). Her talk will focus on “role of EMT transition states during tumorigenesis”

  • Friday 24th of Januaryat 11.30 am in the ONCORA meeting room (CLB, 2nd floor).
    We are pleased to welcome Eric Letouzé (UMRS1138, « Functional Genomics of Solid Tumors » team, Centre de Recherche des Cordeliers, Paris). His talk will focus on: "Computational analysis of liver cancer genomes reveals new mutational signatures and driver events”


  • 4th International Symposium of the CRCL

The Cancer Research Center of Lyon (CRCL) is pleased to announce that its 
4th International Cancer Symposium / Cancer Research Center of Lyon will take place from the 2nd to the 4th of October in the Convention Center of Lyon, France.

This edition should not fall short of its predecessors, since top-ranking internationally renowned researchers, including one of the 2009 Nobel Prize winners in Chemistry, Pr. Ada Yonath, as well as F de Sauvage, JE Visvader, RA Weinberg, and SW Lowe, have already confirmed their attendance. Through the highly diversified presentations of these excellent researchers, the meeting will address crucial issues from both a cognitive and a clinical application standpoint.

Registration and abstract submission on


  • 18th Symposium on Purine and Pyrimidine Metabolism in Man

The 18th Symposium on Purine and Pyrimidine Metabolism in Man will be held in Lyon from 12-14 June 2019 at the International Agency for Research on Cancer.
Registration and abstract submission is open. 
More information on the website :


Co-organized by researchers at Lyon Cancer Research Center (CRCL), the Institute of Nanotechnology of Lyon (INL) and the Institute of Light Matter (ILM), this workshop aims at promoting exchanges and collaborations between physicists and biologists to bring out new concepts in understanding the mechanisms of cancer and in the development of future targeted therapies.

Abstract sumission and registration deadline : February, 15th
More information :

  • 2nd Innate Sensors community (InnaSCo) symposium

The 2nd Innate Sensors community (InnaSCo) symposium will be held in Lyon, France 15th-16th May 2019.

By attending you will have the opportunity to discuss your work and hear talks given by excellent scientists working in the field of Innate immune sensing and disease. Renowed scientists, including as a keynote speaker Nicolas Manel from the Curie Institute have accepted to give invited lectures for this second symposium. Several slots for short talks are available and we encourage everyone including students and post-doctoral fellows to submit an abstract.

Selection of talks and posters will be based on abstract submission. In addition, prizes for the best talk and poster will be awarded.


Deadline for registration and abstract submission 15th March 2019.

Registration is free but compulsory and places are limited:



  • Science Translational Medicine

Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade.

Although immune checkpoint–targeted therapies are currently revolutionizing cancer care, only a minority of patients develop durable objective responses to anti–PD-1, PD-L1, and CTLA-4 therapy. Therefore, new therapeutic interventions are needed to increase the immunogenicity of tumors and overcome the resistance to these immunotherapies. Oncolytic properties of common viruses can be exploited for the priming of antitumor immunity, and such oncolytic viruses are currently in active clinical development in combination with immune checkpoint–targeted therapies.


DOI: 10.1126/scitranslmed.aat5025

  • LKB1 specifies neural crest cell fates through pyruvate-alanine cycling

Résultat de recherche d'images pour 'science advances' Metabolic Processes underlying the development of the neural crest, an embryonic population of multipotent migratory cells, are poorly understood. Here, we report that conditional ablation of the Lkb1 tumor suppressor kinase in mouse neural crest stem cells led to intestinal pseudo-obstruction and hind limb paralysis. This phenotype originated from a postnatal degeneration of the enteric nervous ganglia and from a defective differentiation of Schwann cells. Metabolomic profiling revealed that pyruvate-alanine conversion is enhanced in the absence of Lkb1. Mechanistically, inhibition of alanine transaminases restored glial differentiation in an mTOR-dependent manner, while increased alanine level directly inhibited the glial commitment of neural crest cells. Treatment with the metabolic modulator AICAR suppressed mTOR signaling and prevented Schwann cell and enteric defects of Lkb1 mutant mice. These data uncover a link between pyruvate-alanine cycling and the specification of glial cell fate with potential implications in the understanding of the molecular pathogenesis of neural crest diseases.
DOI : 10.1126/sciadv.aau5106

  • The Proto-oncogene c-Kit Inhibits Tumor Growth by Behaving as a Dependence Receptor

c-Kit is a classic proto-oncogene either mutated or upregulated in cancer cells, and this leads to its constitutive kinase activation and, thus, to uncontrolled proliferation. Although the pro-oncogenic role of c-Kit is of no doubt, some observations do not fit well with c-Kit solely as a tumor-promoting moiety. We show here that c-Kit actively triggers cell death in various cancer cell lines unless engaged by its ligand stem cell factor (SCF). This pro-death activity is enhanced when the kinase activation of c-Kit is silenced and is due to c-Kit intracellular cleavage by caspase-like protease at D816. Moreover, in vivo, overexpression of a c-Kit kinase-dead mutant inhibits tumor growth, and this intrinsic c-Kit tumor-suppressive activity is dependent on the D816 cleavage. Thus, c-Kit acts both as a proto-oncogene via its kinase activity and as a tumor suppressor via its dependence receptor activity.


  • Jauary 2020 - Post-doctoral position

The laboratory of Dr. Julien C. Marie is seeking an experienced, creative and autonomous post-doctoral fellow to study the effects of TGF-B on T cell-biology.
More information

  • Novembrer 2019 - Project manager in immunology

The Laboratory of Immunotherapy of Cancer of Lyon (LICL) is currently seeking a talented and experienced immunologist to coordinate the scientific and technological projects within the lab.
The LICL is affiliated to the CRCL and the Léon Bérard Center.
More information

  • Octobre 2019 - Assistant Ingénieur

Dans le cadre d'un projet visant à étudier les activités de cellules isolées, à l'aide d'induction  in vitro et d'analyse single-cell, le Dr. Martinez recherche un assistant ingénieur. Le déroulement impliquera une collaboration étroite avec deux équipes du Centre de Recherche en Cancérologie de Lyon avec le support de la plateforme et des équipements single-cell du centre.
Plus d'information.

  • Octobre 2019 - Lab manager (assistant ingénieur / ingénieur d'étude)

L’équipe ‘Régulation Moléculaire de l’Immunité dans le Cancer’ recherche un lab manager en CDD, de niveau assistant ingénieur/ingénieur d’études, pour participer à la gestion du laboratoire et gérer un projet scientifique concernant l’étude des protéines NF-kappaB dans le microenvironnement tumoral.
Plus d'information

  • October 2019 - Postdoctoral position

A postdoctoral position is open for a motivate candidate to join the team "Development, cancer and stem cells". The selected applicant will be funded for one year, renewable for an additional year. He/She will under the supervision of Dr. Plateroti and in collaboration with other team members within the framework of the program funded by the Institut National du Cancer (Inca PLBIO 2019).
More information

  • Octobre 2019 - Projet de thèse

L'équipe "Mécanismes de la pathogénèse de l'hépatite B et C chronique et nouvelles stratégies antivirales" dirigée par Fabien Zoulim propose un projet de thèse avec alloctation dotorale ANRS.
Titre du sujet de thèse :
Role of the histone chaperone complex HIRA and HBV Core protein in
histone deposition on hepatitis B virus minichromosome.
Plus d'information

  • Septembre 2019 - Chef de projet

Dans le cadre du projet européen H2020 « IP-cure-B », l'équipe "Viral Hepatitis & Pathobiology of Chronic liver disease", dirigée par Fabien Zoulim, recherche un chef de projet ayant pour mission la gestion financière et administrative du laboratoire ainsi que la gestion des contrats de recherche européens.
Plus d'informations

  • August 2019 - postdoctoral position in bioinformatics

The "cell-death and chilhood cancer" team offers a 1-year contract for a postdoctoral position in bioinformatics applied to Next Generation Sequencing and Illumina technology.
More information

  • August 2019 - Postdoctoral position

The "cell-death and chilhood cancer team" offers a postdoctoral position.
Available for highly motivated post-doctoral fellow interested in conducting interdisciplinary research using in-vitro and in-silico approaches to develop innovative neuroblastoma models and use them to better understand the mechanisms of resistance to treatment in these pathologies.
More information

  • Mai 2019 - Assistant Ingénieur ou Ingénieur d'Etude en immuno-oncologie

L’AI/IE participera à la conception, la réalisation mais aussi au suivi d’expériences réalisées dans le cadre de projets de recherche en immuno-oncologie développés dans le groupe du Dr Nathalie Bendriss-Vermare (CRCN INSERM, HDR) au sein de l’équipe dirigée par le Dr Christophe Caux au Centre de Recherche en Cancérologie de Lyon (CRCL).
Plus d'information

Copyright 2011. CRCL